207 related articles for article (PubMed ID: 10489625)
1. Molecular alterations in bladder cancer.
Cordon-Cardo C
Cancer Surv; 1998; 32():115-31. PubMed ID: 10489625
[TBL] [Abstract][Full Text] [Related]
2. Genetic and molecular markers of urothelial premalignancy and malignancy.
Cordon-Cardo C; Cote RJ; Sauter G
Scand J Urol Nephrol Suppl; 2000; (205):82-93. PubMed ID: 11144907
[TBL] [Abstract][Full Text] [Related]
3. Alterations of tumor suppressor genes in bladder cancer.
Cordon-Cardo C; Reuter VE
Semin Diagn Pathol; 1997 May; 14(2):123-32. PubMed ID: 9179973
[TBL] [Abstract][Full Text] [Related]
4. Occurrence of chromosome 9 and p53 alterations in multifocal dysplasia and carcinoma in situ of human urinary bladder.
Hartmann A; Schlake G; Zaak D; Hungerhuber E; Hofstetter A; Hofstaedter F; Knuechel R
Cancer Res; 2002 Feb; 62(3):809-18. PubMed ID: 11830537
[TBL] [Abstract][Full Text] [Related]
5. Molecular alterations associated with bladder cancer initiation and progression.
Cordon-Cardo C
Scand J Urol Nephrol Suppl; 2008 Sep; (218):154-65. PubMed ID: 18815930
[TBL] [Abstract][Full Text] [Related]
6. [Molecular changes in development and progression of urothelial carcinoma].
Hartmann A
Verh Dtsch Ges Pathol; 2003; 87():172-84. PubMed ID: 16888910
[TBL] [Abstract][Full Text] [Related]
7. A molecular genetic model of human bladder cancer pathogenesis.
Reznikoff CA; Belair CD; Yeager TR; Savelieva E; Blelloch RH; Puthenveettil JA; Cuthill S
Semin Oncol; 1996 Oct; 23(5):571-84. PubMed ID: 8893868
[TBL] [Abstract][Full Text] [Related]
8. The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer.
Smith ND; Rubenstein JN; Eggener SE; Kozlowski JM
J Urol; 2003 Apr; 169(4):1219-28. PubMed ID: 12629332
[TBL] [Abstract][Full Text] [Related]
9. Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium.
Goebell PJ; Knowles MA
Urol Oncol; 2010; 28(4):409-28. PubMed ID: 20610279
[TBL] [Abstract][Full Text] [Related]
10. Molecular control of the cell cycle in cancer: biological and clinical aspects.
Møller MB
Dan Med Bull; 2003 May; 50(2):118-38. PubMed ID: 12812137
[TBL] [Abstract][Full Text] [Related]
11. Value of multicolour fluorescence in situ hybridisation (UroVysion) in the differential diagnosis of flat urothelial lesions.
Schwarz S; Rechenmacher M; Filbeck T; Knuechel R; Blaszyk H; Hartmann A; Brockhoff G
J Clin Pathol; 2008 Mar; 61(3):272-7. PubMed ID: 17693577
[TBL] [Abstract][Full Text] [Related]
12. Patterns of chromosomal aberrations in urinary bladder tumours and adjacent urothelium.
Steidl C; Simon R; Bürger H; Brinkschmidt C; Hertle L; Böcker W; Terpe HJ
J Pathol; 2002 Sep; 198(1):115-20. PubMed ID: 12210071
[TBL] [Abstract][Full Text] [Related]
13. Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese?
Knowles MA
Carcinogenesis; 2006 Mar; 27(3):361-73. PubMed ID: 16352616
[TBL] [Abstract][Full Text] [Related]
14. Frequent genetic alterations in flat urothelial hyperplasias and concomitant papillary bladder cancer as detected by CGH, LOH, and FISH analyses.
Obermann EC; Junker K; Stoehr R; Dietmaier W; Zaak D; Schubert J; Hofstaedter F; Knuechel R; Hartmann A
J Pathol; 2003 Jan; 199(1):50-7. PubMed ID: 12474226
[TBL] [Abstract][Full Text] [Related]
15. Genetic pathways of two types of gastric cancer.
Tahara E
IARC Sci Publ; 2004; (157):327-49. PubMed ID: 15055305
[TBL] [Abstract][Full Text] [Related]
16. Molecular cytogenetic evaluation of virus-associated and non-viral hepatocellular carcinoma: analysis of 26 carcinomas and 12 concurrent dysplasias.
Zondervan PE; Wink J; Alers JC; IJzermans JN; Schalm SW; de Man RA; van Dekken H
J Pathol; 2000 Oct; 192(2):207-15. PubMed ID: 11004697
[TBL] [Abstract][Full Text] [Related]
17. [Tracking the gatekeeper gene in the stages of carcinogenesis in the bladder].
Baud E; Catilina P; Bignon YJ
Bull Cancer; 1997 Oct; 84(10):971-5. PubMed ID: 9435799
[TBL] [Abstract][Full Text] [Related]
18. Active cell death (apoptosis) and cellular proliferation as indicators of exposure to carcinogens.
Schulte-Hermann R; Bursch W; Marian B; Grasl-Kraupp B
IARC Sci Publ; 1999; (146):273-85. PubMed ID: 10353391
[TBL] [Abstract][Full Text] [Related]
19. TP53 alterations as a potential diagnostic marker in superficial bladder carcinoma and in patients serum, plasma and urine samples.
Dahse R; Utting M; Werner W; Schimmel B; Claussen U; Junker K
Int J Oncol; 2002 Jan; 20(1):107-15. PubMed ID: 11743649
[TBL] [Abstract][Full Text] [Related]
20. p16ink4 immunoreactivity is a reliable marker for urothelial carcinoma in situ.
Yin M; Bastacky S; Parwani AV; McHale T; Dhir R
Hum Pathol; 2008 Apr; 39(4):527-35. PubMed ID: 18234280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
